Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 5/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 4/20 | 0.38 |
| ▸ | PARP1 | P09874 | 4/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29518273 | 1.00 | LMNA (0.41) | LMNAMAPK1HTTHSD11B1CALCRL | |
| SCHEMBL24368248 | 0.89 | LMNA (0.43) | LMNAMAPK1HTTHSD11B1CALCRL | |
| SCHEMBL24368352 | 0.89 | LMNA (0.42) | LMNAMAPK1HTTHSD11B1CALCRL | |
| SCHEMBL29518269 | 0.89 | LMNA (0.42) | LMNAMAPK1HTTHSD11B1CALCRL | |
| SCHEMBL29518257 | 0.87 | ECE2 (0.48) | LMNAMAPK1HTTHSD11B1CALCRL | |
| SCHEMBL22605456 | 0.87 | ECE2 (0.48) | LMNAMAPK1HTTHSD11B1CALCRL | |
| SCHEMBL29518321 | 0.85 | PLD2 (0.45) | LMNAMAPK1HTTHSD11B1CALCRL | |
| SCHEMBL22605644 | 0.85 | PLD2 (0.45) | LMNAMAPK1HTTHSD11B1CALCRL | |
| SCHEMBL24368305 | 0.82 | CALCRL (0.42) | LMNAMAPK1HTTHSD11B1CALCRL | |
| SCHEMBL29518774 | 0.82 | CALCRL (0.42) | LMNAMAPK1HTTHSD11B1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391940-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (GB) | 2024-11-28 | — | — | US | disclosed |
| EP-4234544-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | Generos Biopharma Ltd. (KY) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234544-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | Generos Biopharma Ltd. (KY) | 2023-08-30 | — | — | EP | disclosed |
| CN-116457347-A | Compound containing condensed rings, application thereof and composition containing compound | 健艾仕生物医药有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-114478482-A | Compound containing condensed ring, application thereof and composition containing compound | 健艾仕生物医药有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022083731-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391940-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | STAT5A, STAT5B, JAK2 | LMNA 4799/4885MAPK1 731/4885HTT 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.